We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ITW:NYSEIllinois Tool Works Inc. Analysis

Data as of 2026-05-24 - not real-time

$252.20

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Illinois Tool Works posted Q1 2026 revenue of $4.02 billion, up 4.6% YoY, beating consensus. GAAP EPS came in at $2.66, a 3.5% beat, and operating margin improved to 25.4%, adding 60 bps. Management highlighted strong demand in automotive and construction segments and announced a 2.55% dividend. Despite the beat, the stock slipped roughly 3% on the day, reflecting profit‑taking and lingering concerns over leverage. The company’s free cash flow of $2.22 billion supports the dividend payout of $6.44 per share, yielding 2.55%. However, total debt of $9.15 billion versus cash of $0.83 billion leaves a debt‑to‑equity ratio above 280%.
On the technical side, ITW trades at $252.20, below its 20‑day SMA of 254.8 and 50‑day SMA of 261.2, with a neutral RSI of 43.7. The MACD histogram turned positive, indicating a mild bullish tilt, but volume is on a downtrend. Valuation metrics are mixed: a trailing PE of 23.4 is below the industry average of 29.7, yet a discounted‑cash‑flow model pins fair value near $93, implying significant overvaluation. The extreme‑greed sentiment index (91.6) suggests market enthusiasm may be overstated. High ROE (96.8%) is driven largely by leverage, and the beta of 0.63 points to lower market volatility. Overall, the stock offers a solid dividend and resilient margins but faces valuation pressure and debt risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Q1 earnings beat but price fell 3% post‑release
  • High debt‑to‑equity ratio (≈280%) raises balance‑sheet risk
  • Technical price below short‑term moving averages

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong free cash flow sustains dividend payout
  • Operating margins expanding modestly
  • Valuation remains above DCF fair value

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustainable dividend yield of 2.55%
  • Diversified global exposure across industrial segments
  • Potential valuation correction due to leverage

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin19.32%
P/E Ratio23.4
ROE96.85%
ROA17.04%
Debt/Equity283.22
P/B Ratio22.5
Op. Cash Flow$3.2B
Free Cash Flow$2.2B
Industry P/E29.7

Technical Analysis

TrendNeutral
RSI43.7
Support$244.37
Resistance$273.25
MA 20$254.81
MA 50$261.23
MA 200$260.84
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair Value$93.18
Target Price$274.54
Upside/Downside8.86%
GradeOvervalued
TypeBlend
Dividend Yield2.55%

Risk Assessment

Beta0.63
Volatility22.14%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.